医生/博士学士实习生紧急医疗住院途径:对医生科学家培训计划的全国横截面研究
Karen Cyndari1, Libby White1, Philip A Mudd2
1Department of Emergency Medicine University of Iowa Carver College of Medicine Iowa City Iowa USA.
AEM education and training
|March 25, 2024
概括
紧急医疗 (EM) 住院计划越来越多地为医生科学家MD/博士毕业生提供研究培训. 虽然大多数课程都重视研究,但专门的医生科学家培训途径尚未普及.
科学领域:
- 医学教育 医学教育
- 医生科学家培训 医生科学家培训
- 紧急医疗研究 紧急医疗研究
背景情况:
- 结合临床和研究培训对于追求医生科学家职业的医学博士毕业生至关重要.
- 紧急医疗 (EM) 计划可能缺乏对研究专注的学员资源的明确性.
- 实习生需要有关EM计划的指导,支持医生科学家的发展.
研究的目的:
- 描述研究培训和资源的MD/博士学位毕业生在EM居住.
- 在EM居住计划中确定专门的研究途径.
主要方法:
- 对EM住院计划主管进行横截面电子调查.
- 调查专门的MD/PhD研究培训途径,资源和优先事项.
- 描述性统计数据,以总结调查答复.
主要成果:
- 收集了192份调查答复 (69.6%的回复率).
- 21.4%的课程提供研究途径/轨道,27.4%提供研究奖学金.
- 11.5%提供了两者,1.0%提供了一个专门的EM医生-科学家途径. 医生科学家的招聘没有优先考虑.
结论:
- 一些EM住院计划为医生科学家提供联合临床和研究培训.
- 几乎所有的EM课程都认识到研究的重要性.
- 未来的努力应该优化居住和奖学金途径,以增强EM医生科学家管道.
相关概念视频
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


